233 related articles for article (PubMed ID: 29566337)
21. BCL9 Upregulation in Adrenocortical Carcinoma: A Novel Wnt/β-Catenin Activating Event Driving Adrenocortical Malignancy.
Brown TC; Nicolson NG; Korah R; Carling T
J Am Coll Surg; 2018 Jun; 226(6):988-995. PubMed ID: 29428231
[TBL] [Abstract][Full Text] [Related]
22. Nerve growth factor modulates the tumor cells migration in ovarian cancer through the WNT/β-catenin pathway.
Li B; Cai S; Zhao Y; He Q; Yu X; Cheng L; Zhang Y; Hu X; Ke M; Chen S; Zou M
Oncotarget; 2016 Dec; 7(49):81026-81048. PubMed ID: 27835587
[TBL] [Abstract][Full Text] [Related]
23. BCL9 promotes epithelial mesenchymal transition and invasion in cisplatin resistant NSCLC cells via β-catenin pathway.
Zhang Y; Zhang Q; Chen H; Wang C
Life Sci; 2018 Sep; 208():284-294. PubMed ID: 30009824
[TBL] [Abstract][Full Text] [Related]
24. Targeted disruption of the BCL9/β-catenin interaction by endosomal-escapable nanoparticles functionalized with an E-cadherin-derived peptide.
Yang G; Zhang J; You W; Zhao X; Hou P; He W; Yan J; Guo H
Nanotechnology; 2020 Mar; 31(11):115102. PubMed ID: 31751960
[TBL] [Abstract][Full Text] [Related]
25. Baicalein suppresses metastasis of breast cancer cells by inhibiting EMT via downregulation of SATB1 and Wnt/β-catenin pathway.
Ma X; Yan W; Dai Z; Gao X; Ma Y; Xu Q; Jiang J; Zhang S
Drug Des Devel Ther; 2016; 10():1419-41. PubMed ID: 27143851
[TBL] [Abstract][Full Text] [Related]
26. The Discovery and Characterization of K-756, a Novel Wnt/β-Catenin Pathway Inhibitor Targeting Tankyrase.
Okada-Iwasaki R; Takahashi Y; Watanabe Y; Ishida H; Saito J; Nakai R; Asai A
Mol Cancer Ther; 2016 Jul; 15(7):1525-34. PubMed ID: 27196752
[TBL] [Abstract][Full Text] [Related]
27. Rational design of small-molecule inhibitors for β-catenin/T-cell factor protein-protein interactions by bioisostere replacement.
Yu B; Huang Z; Zhang M; Dillard DR; Ji H
ACS Chem Biol; 2013 Mar; 8(3):524-9. PubMed ID: 23272635
[TBL] [Abstract][Full Text] [Related]
28. Structure-based discovery of a novel inhibitor targeting the β-catenin/Tcf4 interaction.
Tian W; Han X; Yan M; Xu Y; Duggineni S; Lin N; Luo G; Li YM; Han X; Huang Z; An J
Biochemistry; 2012 Jan; 51(2):724-31. PubMed ID: 22224445
[TBL] [Abstract][Full Text] [Related]
29. Direct targeting of β-catenin in the Wnt signaling pathway: Current progress and perspectives.
Wang Z; Li Z; Ji H
Med Res Rev; 2021 Jul; 41(4):2109-2129. PubMed ID: 33475177
[TBL] [Abstract][Full Text] [Related]
30. The anthelmintic niclosamide inhibits colorectal cancer cell lines via modulation of the canonical and noncanonical Wnt signaling pathway.
Monin MB; Krause P; Stelling R; Bocuk D; Niebert S; Klemm F; Pukrop T; Koenig S
J Surg Res; 2016 Jun; 203(1):193-205. PubMed ID: 27338550
[TBL] [Abstract][Full Text] [Related]
31. miR-122 enhances sensitivity of hepatocellular carcinoma to oxaliplatin via inhibiting MDR1 by targeting Wnt/β-catenin pathway.
Cao F; Yin LX
Exp Mol Pathol; 2019 Feb; 106():34-43. PubMed ID: 30539797
[TBL] [Abstract][Full Text] [Related]
32. BCL9-2 binds Arm/beta-catenin in a Tyr142-independent manner and requires Pygopus for its function in Wg/Wnt signaling.
Hoffmans R; Basler K
Mech Dev; 2007 Jan; 124(1):59-67. PubMed ID: 17113272
[TBL] [Abstract][Full Text] [Related]
33. Lawsone derivatives target the Wnt/β-catenin signaling pathway in multidrug-resistant acute lymphoblastic leukemia cells.
Hamdoun S; Fleischer E; Klinger A; Efferth T
Biochem Pharmacol; 2017 Dec; 146():63-73. PubMed ID: 29061340
[TBL] [Abstract][Full Text] [Related]
34. Discovery of small molecule inhibitors of the Wnt/β-catenin signaling pathway by targeting β-catenin/Tcf4 interactions.
Yan M; Li G; An J
Exp Biol Med (Maywood); 2017 Jun; 242(11):1185-1197. PubMed ID: 28474989
[TBL] [Abstract][Full Text] [Related]
35. 1-Benzyl-indole-3-carbinol is a highly potent new small molecule inhibitor of Wnt/β-catenin signaling in melanoma cells that coordinately inhibits cell proliferation and disrupts expression of microphthalmia-associated transcription factor isoform-M.
Kundu A; Khouri MG; Aryana S; Firestone GL
Carcinogenesis; 2017 Dec; 38(12):1207-1217. PubMed ID: 29028954
[TBL] [Abstract][Full Text] [Related]
36. FNC, a novel nucleoside analogue, blocks invasion of aggressive non-Hodgkin lymphoma cell lines via inhibition of the Wnt/β-catenin signaling pathway.
Zhang Y; Wang CP; Ding XX; Wang N; Ma F; Jiang JH; Wang QD; Chang JB
Asian Pac J Cancer Prev; 2014; 15(16):6829-35. PubMed ID: 25169533
[TBL] [Abstract][Full Text] [Related]
37. Discovery of 2-(isoxazol-5-yl)phenyl 3,4-dihydroxybenzoate as a potential inhibitor for the Wnt/β-catenin pathway.
Dong Y; Liu M; Mao Y; Wu S; Wen J; Lu J; Yang Y; Ruan S; Li L; Liu X; Zhang J; Liao S; Dong L
Bioorg Chem; 2022 Nov; 128():106116. PubMed ID: 36063753
[TBL] [Abstract][Full Text] [Related]
38. A silyl andrographolide analogue suppresses Wnt/β-catenin signaling pathway in colon cancer.
Reabroi S; Chairoungdua A; Saeeng R; Kasemsuk T; Saengsawang W; Zhu W; Piyachaturawat P
Biomed Pharmacother; 2018 May; 101():414-421. PubMed ID: 29501763
[TBL] [Abstract][Full Text] [Related]
39. Preferential Inhibition of Wnt/β-Catenin Signaling by Novel Benzimidazole Compounds in Triple-Negative Breast Cancer.
Gangrade A; Pathak V; Augelli-Szafran CE; Wei HX; Oliver P; Suto M; Buchsbaum DJ
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29783777
[TBL] [Abstract][Full Text] [Related]
40. Is β-Catenin a Druggable Target for Cancer Therapy?
Cui C; Zhou X; Zhang W; Qu Y; Ke X
Trends Biochem Sci; 2018 Aug; 43(8):623-634. PubMed ID: 30056837
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
